Blood-clotting protein implicated in cognitive decline and Alzheimer's

  • A blood-clotting protein called fibrinogen has been shown to provoke the brain's immune cells into destroying synapses. The process begins with fibrinogen leaking from the blood into the brain.
  • Another study has found that nearly half of all dementias begin with a breakdown of the gatekeeper cells (pericytes) that help keep fibrinogen out of the brain.

Alzheimer's disease is associated with abnormalities in the vast network of blood vessels in the brain, but it hasn’t been known how this affects cognition. A study has now shown that a blood-clotting protein called fibrinogen plays a part.

The study found that fibrinogen, after leaking from the blood into the brain, activates the brain's immune cells and triggers them to destroy synapses, which are critical for neuronal communication.

Loss of synapses is known to cause memory loss, and the study found that preventing fibrinogen from activating the brain's immune cells protected Alzheimer's mice from memory loss.

Moreover, fibrinogen had this effect even in brains that lack amyloid plaques.

The findings help explain how elderly people with vascular pathology could show similar rates of cognitive decline as age-matched people with amyloid pathology. The same human studies also found that those with both types of pathology had much worse and more rapid cognitive decline.

Another study suggests that nearly half of all dementias, including Alzheimer's, begins with the breakdown of the smallest blood vessels in the brain and the "gatekeeper cells" that surround and protect the capilleries.

The collapse of pericytes (the gatekeeper cells) reduces myelin and white matter structure in the brain. They do this via fibrinogen. Fibrinogen develops blood clots so wounds can heal but when the gatekeeper cells fail, too much fibrinogen enters the brain and causes white matter to die.

Mouse studies showed that controlling fibrinogen levels can reverse or slow white matter disease.

Postmortem study of human brains found that Alzheimer’s brains had about 50% fewer gatekeeper cells and three times more fibrinogen proteins in watershed white matter areas, compared to healthy brains.

The mouse study found that white matter changes in mice began as early as 12 to 16 weeks old, the equivalent of 40 years in humans.

When an enzyme known to reduce fibrinogen was introduced into the mice, white matter volume returned to 90% of their normal state, and white matter connections were back to 80% productivity.

https://www.eurekalert.org/pub_releases/2019-02/gi-anc020519.php

https://www.eurekalert.org/pub_releases/2018-02/uosc-hoa020218.php

Reference: 

Related News

Analysis of 40 spinal marrow samples, 20 of which belonged to Alzheimer’s patients, has identified six

Blocking a receptor involved in inflammation in the brains of mice with severe Alzheimer’s produced marked recovery in blood flow and vascular reactivity, a dramatic reduction in toxic amyloid-beta, and significant improvements in learning and memory.

A multi-year study involving 207 healthy older adults, in which their spinal fluids were repeatedly sampled and their brains repeatedly scanned, has found that disruptions in the default mode network emerges about the same time as chemical markers of Alzheimer’s appear in the spinal fluid (decre

The first detailed characterization of the molecular structures of amyloid-beta fibrils that develop in the brains of those with Alzheimer's disease suggests that different molecular structures of amyloid-beta fibrils may distinguish the brains of Alzheimer's patients with different clinical his

A study involving mice lacking a master clock gene called Bmal1 has found that as the mice aged, their brains showed patterns of damage similar to those seen in Alzheimer's disease and other neurodegenerative disorders. Many of the injuries seemed to be caused by free radicals.

A new study involving 96 older adults initially free of dementia at the time of enrollment, of whom 12 subsequently developed mild Alzheimer’s, has clarified three fundamental issues about Alzheimer's: where it starts, why it starts there, and how it spreads.

Analysis of 5715 cases from the National Alzheimer's Coordinating Center (NACC) database has found that nearly 80% of more than 4600 Alzheimer's disease patients showed some degree of vascular pathology, compared with 67% of the controls, and 66% in the Parkinson's group.

The

Analyses of cerebrospinal fluid from 15 patients with Alzheimer's disease, 20 patients with mild cognitive impairment, and 21 control subjects, plus brain tissue from

Tau protein stabilizes structures that transport supplies from the center of the cell to the extremities, but sometimes some tau is not bound to these microtubules and instead clumps together into

Pages

Subscribe to Latest newsSubscribe to Latest newsSubscribe to Latest health newsSubscribe to Latest news